Scarica l'app Stockscreener
20.51
20.79%
3.53
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Can Zenas BioPharma Inc. hit a new high this monthWeekly Trend Summary & High Return Trade Opportunity Guides - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteria2025 Performance Recap & Technical Pattern Alert System - Newser
How institutional ownership impacts Zenas BioPharma Inc. stockBond Market & Weekly Return Optimization Alerts - Newser
What machine learning models say about Zenas BioPharma Inc.2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
Tick level data insight on Zenas BioPharma Inc. volatilityBond Market & Fast Entry Momentum Trade Alerts - Newser
Pattern recognition hints at Zenas BioPharma Inc. upsideInsider Buying & Reliable Breakout Forecasts - Newser
Insiders Rewarded With US$1.5m Addition To Investment As Zenas BioPharma Stock Hits US$864m - simplywall.st
Can Zenas BioPharma Inc. reach all time highs this yearPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Can Zenas BioPharma Inc. deliver consistent dividendsJuly 2025 Summary & Expert-Curated Trade Recommendations - خودرو بانک
Nuveen LLC Buys Shares of 31,626 Zenas BioPharma, Inc. $ZBIO - Defense World
Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
Wedbush Has Bullish Outlook for Zenas BioPharma Q3 Earnings - Defense World
Quantitative breakdown of Zenas BioPharma Inc. recent moveDip Buying & Fast Gain Swing Trade Alerts - Newser
Is Zenas BioPharma Inc.’s growth already priced inEarnings Trend Report & Daily Profit Focused Screening - خودرو بانک
Block Trades: What is Zenas BioPharma Inc.’s TAM (Total Addressable Market)July 2025 Recap & High Yield Stock Recommendations - خودرو بانک
Using data models to predict Zenas BioPharma Inc. stock movementPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Measuring Zenas BioPharma Inc.’s beta against major indicesJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
What MACD and RSI say about Zenas BioPharma Inc.Portfolio Growth Summary & Daily Growth Stock Tips - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceRecession Risk & Precise Buy Zone Tips - Newser
Royalty Pharma's Strategic Position in the Biopharma Royalty Space - AInvest
Using fundamentals and technicals on Zenas BioPharma Inc.July 2025 Outlook & Growth Oriented Trade Recommendations - Newser
Technical signs of recovery in Zenas BioPharma Inc.Weekly Stock Report & Weekly Setup with High ROI Potential - Newser
Is Zenas BioPharma Inc. still a buy after recent gainsWeekly Investment Report & Reliable Entry Point Trade Alerts - beatles.ru
How moving averages guide Zenas BioPharma Inc. tradingWeekly Trade Recap & Precise Trade Entry Recommendations - Newser
Chart based exit strategy for Zenas BioPharma Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
Will Zenas BioPharma Inc. price bounce be sustainable2025 Fundamental Recap & Accurate Entry/Exit Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsGap Down & Community Driven Trade Alerts - Newser
What’s the RSI of Zenas BioPharma Inc. stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - خودرو بانک
Is Zenas BioPharma Inc. stock overvalued or fairly pricedJuly 2025 Catalysts & Short-Term Swing Trade Alerts - خودرو بانک
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - خودرو بانک
Zenas Biopharma shares fall 2.28% intraday as Royalty Pharma announces $2.0 billion offering. - AInvest
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):